Retractable Technologies, Inc. (RVP)

Retractable Technologies, Inc.'s stock price has declined by 36.18% over the past six months. The third-quarter 2025 earnings announcement led to a 14.2% stock decline due to operating losses and decreased net sales. The company faced increased cost pressures from tariffs, incurring $172,000 in Q3 2025 and $2.3 million over the first nine months of 2025. Following its earnings release for the quarter ended December 31, 2025, the stock lost 3.1%, despite a 15.8% increase in full-year 2025 revenues to $38.3 million. Upcoming financial events include a dividend record date on April 10, 2026, and a dividend payment date on April 20, 2026, for Series II and Series III Class B preferred dividends.

Retractable Technologies, Inc. experienced significant revenue growth from late 2020 through early 2022 due to substantial orders from the U.S. government for syringes to support COVID-19 vaccination efforts. Lingering inventory overhang from pandemic-era vaccine demand has dampened domestic purchasing activity, suppressing near-term demand visibility.

Retractable Technologies, Inc. specializes in the design, development, manufacturing, and marketing of safety medical products, focusing on injection, blood collection, and infusion devices. Major products are marketed under the VanishPoint, EasyPoint, and Patient Safe brands. The VanishPoint line prevents needlestick injuries and product reuse. Patient Safe syringes reduce the risk of bloodstream infections. EasyPoint retractable needles can be used with various luer lock, luer slip, and prefilled syringes.

Retractable Technologies, Inc. distributes its products through specialty and general line distributors, international distributors, and a national direct marketing network. The company's business involves both domestic and international sales, with operations extending across the United States, the rest of North and South America, and internationally.

Retractable Technologies has received positive recognition for its products, such as the EasyPoint Blood Collection Tube Holder with Needle receiving an Innovative Technology designation from Vizient. Media sentiment regarding Retractable Technologies in the past week has been neutral. The company reported a workforce reduction of approximately 16%.

Retractable Technologies, Inc. has 33 institutional owners and shareholders holding a total of 2,632,586 shares. Major institutional owners include Vanguard Group Inc, Eversept Partners, LP, Renaissance Technologies Llc, BlackRock, Inc., Geode Capital Management, Llc, Bridgeway Capital Management Inc, Citadel Advisors Llc, State Street Corp, WealthTrust Axiom LLC, and LPL Financial LLC. Thomas J. Shaw, the CEO, is the largest individual shareholder, owning 24.76 million shares, representing 82.72% of the company.